[go: up one dir, main page]

MA31571B1 - Composes organiques - Google Patents

Composes organiques

Info

Publication number
MA31571B1
MA31571B1 MA32544A MA32544A MA31571B1 MA 31571 B1 MA31571 B1 MA 31571B1 MA 32544 A MA32544 A MA 32544A MA 32544 A MA32544 A MA 32544A MA 31571 B1 MA31571 B1 MA 31571B1
Authority
MA
Morocco
Prior art keywords
compounds
organic compounds
alk
meanings
receptor
Prior art date
Application number
MA32544A
Other languages
English (en)
Inventor
Dimitros Lizos
Sven Weiler
Nikolaus Johannes Stiefl
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MA31571B1 publication Critical patent/MA31571B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Virology (AREA)
  • Neurology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Communicable Diseases (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Psychiatry (AREA)
  • Reproductive Health (AREA)
  • Biotechnology (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Vascular Medicine (AREA)

Abstract

L'INVENTION PORTE SUR DES COMPOSÉS DE FORMULE (I) SOUS FORME LIBRE, DE SEL OU DE SOLVATE, OÙ R1, R2 ET R5 ONT LES SIGNIFICATIONS TELLES QU'INDIQUÉES DANS LA DESCRIPTION, LESQUELS COMPOSÉS SONT UTILES POUR LE TRAITEMENT DE MALADIES À MÉDIATION PAR LE RÉCEPTEUR ALK-5 ET/OU ALK-4. L'INVENTION PORTE ÉGALEMENT SUR DES COMPOSITIONS PHARMACEUTIQUES QUI CONTIENNENT LES COMPOSÉS ET SUR DES PROCÉDÉS POUR PRÉPARER LES COMPOSÉS.
MA32544A 2007-07-26 2010-01-22 Composes organiques MA31571B1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP07113214 2007-07-26

Publications (1)

Publication Number Publication Date
MA31571B1 true MA31571B1 (fr) 2010-08-02

Family

ID=38694831

Family Applications (1)

Application Number Title Priority Date Filing Date
MA32544A MA31571B1 (fr) 2007-07-26 2010-01-22 Composes organiques

Country Status (22)

Country Link
US (1) US8143253B2 (fr)
EP (1) EP2183027B1 (fr)
JP (1) JP5090528B2 (fr)
KR (1) KR101150581B1 (fr)
CN (1) CN101765442B (fr)
AT (1) ATE522249T1 (fr)
AU (1) AU2008280135B2 (fr)
BR (1) BRPI0813625A2 (fr)
CA (1) CA2694261A1 (fr)
CL (1) CL2008002184A1 (fr)
CO (1) CO6290714A2 (fr)
CR (1) CR11207A (fr)
EA (1) EA201000123A1 (fr)
EC (1) ECSP109898A (fr)
ES (1) ES2375425T3 (fr)
MA (1) MA31571B1 (fr)
PE (1) PE20090506A1 (fr)
SV (1) SV2010003463A (fr)
TN (1) TN2010000040A1 (fr)
TW (1) TW200911814A (fr)
WO (1) WO2009013335A1 (fr)
ZA (1) ZA201000079B (fr)

Families Citing this family (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1932846B1 (fr) * 2005-08-30 2010-10-27 Sumitomo Chemical Company, Limited Procede servant a produire un compose chlorure de sulfonyle
US20110105457A1 (en) * 2008-04-18 2011-05-05 Shionogi & Co., Ltd. Heterocyclic compound having inhibitory activity on pi3k
WO2012013713A2 (fr) * 2010-07-28 2012-02-02 Bayer Pharma Aktiengesellschaft Imidazo[1,2-b]pyridazines substituées
US8754114B2 (en) 2010-12-22 2014-06-17 Incyte Corporation Substituted imidazopyridazines and benzimidazoles as inhibitors of FGFR3
EP2726482B1 (fr) * 2011-07-01 2016-07-20 Bayer Intellectual Property GmbH Pyrrolotriazines substituées par hydroxyméthylaryle utilisées comme inhibiteurs d'alk1
WO2013102145A1 (fr) 2011-12-28 2013-07-04 Global Blood Therapeutics, Inc. Composés d'aldéhydes hétéroaryles substitués et leurs procédés d'utilisation dans l'accroissement de l'oxygénation tissulaire
PE20181519A1 (es) * 2011-12-28 2018-09-21 Global Blood Therapeutics Inc Compuestos de benzaldehido sustituidos y metodos para su uso en incrementar la oxigenacion del tejido
CN107652289B (zh) 2012-06-13 2020-07-21 因塞特控股公司 作为fgfr抑制剂的取代的三环化合物
US9388185B2 (en) 2012-08-10 2016-07-12 Incyte Holdings Corporation Substituted pyrrolo[2,3-b]pyrazines as FGFR inhibitors
SG11201503299YA (en) * 2012-09-28 2015-06-29 Univ Vanderbilt Fused heterocyclic compounds as selective bmp inhibitors
KR20150072412A (ko) * 2012-10-05 2015-06-29 리겔 파마슈티칼스, 인크. Gdf-8 억제제
US9266892B2 (en) 2012-12-19 2016-02-23 Incyte Holdings Corporation Fused pyrazoles as FGFR inhibitors
AP2015008718A0 (en) 2013-03-15 2015-09-30 Global Blood Therapeutics Inc Compounds and uses thereof for the modulation of hemoglobin
US10266551B2 (en) 2013-03-15 2019-04-23 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US10100043B2 (en) 2013-03-15 2018-10-16 Global Blood Therapeutics, Inc. Substituted aldehyde compounds and methods for their use in increasing tissue oxygenation
US9604999B2 (en) 2013-03-15 2017-03-28 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US8952171B2 (en) 2013-03-15 2015-02-10 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US9422279B2 (en) 2013-03-15 2016-08-23 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US9802900B2 (en) 2013-03-15 2017-10-31 Global Blood Therapeutics, Inc. Bicyclic heteroaryl compounds and uses thereof for the modulation of hemoglobin
BR112015021985B1 (pt) 2013-03-15 2022-12-13 Global Blood Therapeutics, Inc Compostos ou sais farmaceuticamente aceitáveis dos mesmos, respectivos usos e composição
US20140274961A1 (en) 2013-03-15 2014-09-18 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US9458139B2 (en) 2013-03-15 2016-10-04 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
JP6463327B2 (ja) 2013-03-15 2019-01-30 グローバル ブラッド セラピューティクス インコーポレイテッド ヘモグロビンの修飾のための化合物及びその使用
KR102269032B1 (ko) 2013-04-19 2021-06-24 인사이트 홀딩스 코포레이션 Fgfr 저해제로서 이환식 헤테로사이클
RU2550346C2 (ru) * 2013-09-26 2015-05-10 Общество с ограниченной ответственностью "Отечественные Фармацевтические Технологии" ООО"ФармТех" Новые химические соединения (варианты) и их применение для лечения онкологических заболеваний
EA202092627A1 (ru) 2013-11-18 2021-09-30 Глобал Блад Терапьютикс, Инк. Соединения и их применения для модуляции гемоглобина
JP6809681B2 (ja) 2014-02-07 2021-01-06 グローバル ブラッド セラピューティクス インコーポレイテッド ２−ヒドロキシ−６−（（２−（１−イソプロピル−１ｈ−ピラゾール−５−イル）ピリジン−３−イル）メトキシ）ベンズアルデヒドの遊離塩基の結晶多形
WO2015157093A1 (fr) * 2014-04-08 2015-10-15 Rigel Pharmaceuticals, Inc. Composés de pyridine 2,3-disubstitués utilisés comme inhibiteurs de tgf-bêta et procédés d'utilisation
US10851105B2 (en) 2014-10-22 2020-12-01 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
WO2016134294A1 (fr) 2015-02-20 2016-08-25 Incyte Corporation Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
PE20171514A1 (es) 2015-02-20 2017-10-20 Incyte Corp Heterociclos biciclicos como inhibidores de fgfr
MA41551A (fr) 2015-02-20 2017-12-26 Incyte Corp Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
MA41841A (fr) 2015-03-30 2018-02-06 Global Blood Therapeutics Inc Composés aldéhyde pour le traitement de la fibrose pulmonaire, de l'hypoxie, et de maladies auto-immunes et des tissus conjonctifs
US11020382B2 (en) 2015-12-04 2021-06-01 Global Blood Therapeutics, Inc. Dosing regimens for 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde
CN105418615B (zh) * 2015-12-09 2018-02-02 北京工业大学 苯甲酰胺衍生物及制备和应用
TWI663160B (zh) 2016-05-12 2019-06-21 全球血液治療公司 用於合成2-羥基-6-((2-(1-異丙基-1h-吡唑-5-基)-吡啶-3-基)甲氧基)苯甲醛之方法
CN106478517A (zh) * 2016-08-31 2017-03-08 安徽省鸿鑫生物科技有限公司 一种2‑甲基5‑氯哒嗪酮的合成方法
CN106478516A (zh) * 2016-08-31 2017-03-08 安徽省鸿鑫生物科技有限公司 一种5‑氯哒嗪酮的合成方法
TW202332423A (zh) 2016-10-12 2023-08-16 美商全球血液治療公司 包含2-羥基-6-((2-(1-異丙基-1h-吡唑-5-基)吡啶-3-基)甲氧基)-苯甲醛之片劑
AR111960A1 (es) 2017-05-26 2019-09-04 Incyte Corp Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
CN107805252A (zh) * 2017-10-25 2018-03-16 上海道亦化工科技有限公司 一种基于咪唑并哒嗪的有机电致发光化合物及其用途和有机电致发光器件
CN111433200B (zh) 2017-12-02 2024-03-22 加拉帕戈斯股份有限公司 用于治疗疾病的化合物及其药物组合物
CN111867581B (zh) 2018-01-29 2023-12-26 默克专利股份有限公司 Gcn2抑制剂及其用途
SG11202006701TA (en) * 2018-01-29 2020-08-28 Merck Patent Gmbh Gcn2 inhibitors and uses thereof
EP3765460A1 (fr) 2018-03-14 2021-01-20 Vanderbilt University Inhibition de la signalisation bmp, composés, compositions et leurs utilisations
SG11202010636VA (en) 2018-05-04 2020-11-27 Incyte Corp Solid forms of an fgfr inhibitor and processes for preparing the same
BR112020022373A2 (pt) 2018-05-04 2021-02-02 Incyte Corporation sais de um inibidor de fgfr
US11014884B2 (en) 2018-10-01 2021-05-25 Global Blood Therapeutics, Inc. Modulators of hemoglobin
SG11202106582YA (en) * 2018-12-20 2021-07-29 Incyte Corp Imidazopyridazine and imidazopyridine compounds as inhibitors of activin receptor-like kinase-2
WO2020163689A1 (fr) 2019-02-08 2020-08-13 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Inhibiteurs de formation de 20-hete
WO2020185532A1 (fr) 2019-03-08 2020-09-17 Incyte Corporation Méthodes de traitement du cancer au moyen d'un inhibiteur de fgfr
WO2021007269A1 (fr) 2019-07-09 2021-01-14 Incyte Corporation Hétérocycles bicycliques en tant qu'inhibiteurs de fgfr
WO2021067374A1 (fr) 2019-10-01 2021-04-08 Incyte Corporation Hétérocycles bicycliques en tant qu'inhibiteurs de fgfr
WO2021076602A1 (fr) 2019-10-14 2021-04-22 Incyte Corporation Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr
WO2021076728A1 (fr) 2019-10-16 2021-04-22 Incyte Corporation Hétérocycles bicycliques en tant qu'inhibiteurs de fgfr
CN115151539A (zh) 2019-12-04 2022-10-04 因赛特公司 Fgfr抑制剂的衍生物
JP7720840B2 (ja) 2019-12-04 2025-08-08 インサイト・コーポレイション Ｆｇｆｒ阻害剤としての三環式複素環
US20230049619A1 (en) 2019-12-19 2023-02-16 Universite De Strasbourg Sigma-1 receptor ligands and uses thereof
WO2021146424A1 (fr) 2020-01-15 2021-07-22 Incyte Corporation Hétérocycles bicycliques en tant qu'inhibiteurs de fgfr
PE20230491A1 (es) * 2020-06-12 2023-03-23 Incyte Corp Compuestos de imidazopiridazina con actividad como inhibidores de alk2
ES2984546T3 (es) 2020-07-15 2024-10-29 Chiesi Farm Spa Derivados de amino pirido-oxazina como inhibidores de ALK5
KR20230051500A (ko) 2020-07-15 2023-04-18 키에시 파르마슈티시 엣스. 피. 에이. Alk5 억제제로서 피리다진일 아미노 유도체
US20240116947A1 (en) 2020-07-15 2024-04-11 Chiesi Farmaceutici S.P.A. Pyrido oxazine derivatives as alk5 inhibitors
WO2022136221A1 (fr) 2020-12-23 2022-06-30 Chiesi Farmaceutici S.P.A. Dérivés de pyrido-oxazine utilisés comme inhibiteurs d'alk5
US12065494B2 (en) 2021-04-12 2024-08-20 Incyte Corporation Combination therapy comprising an FGFR inhibitor and a Nectin-4 targeting agent
AR126102A1 (es) 2021-06-09 2023-09-13 Incyte Corp Heterociclos tricíclicos como inhibidores de fgfr
CA3220155A1 (fr) 2021-06-09 2022-12-15 Incyte Corporation Heterocycles tricycliques utiles en tant qu'inhibiteurs de fgfr
TW202328102A (zh) 2021-09-21 2023-07-16 義大利商吉斯藥品公司 作為ａｌｋ５抑制劑之嗒𠯤基胺基衍生物
EP4514802A1 (fr) 2022-04-27 2025-03-05 Chiesi Farmaceutici S.p.A. Dérivés d'imidazole en tant qu'inhibiteurs d'alk5

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT880523E (pt) 1996-02-07 2007-01-31 Neurocrine Biosciences Inc Pirazolopirimidinas com antagonistas dos receptores de crf
KR20010087738A (ko) * 1998-10-21 2001-09-21 다케다 야쿠힌 고교 가부시키가이샤 축합 피리다진 유도체, 이의 제조 방법 및 용도
GB0103926D0 (en) * 2001-02-17 2001-04-04 Astrazeneca Ab Chemical compounds
KR20050115252A (ko) 2003-02-28 2005-12-07 데이진 화-마 가부시키가이샤 피라졸로[1,5-ａ]피리미딘 유도체
JP4758909B2 (ja) * 2003-12-31 2011-08-31 シェーリング−プラウ・リミテッド イミダゾ［１，２−ｂ］ピリダジン誘導体を使用することによる動物における寄生生物の制御
CN101098870B (zh) * 2004-11-08 2010-11-03 万有制药株式会社 新型稠环咪唑衍生物
JP4971300B2 (ja) 2005-03-21 2012-07-11 イーライ リリー アンド カンパニー イミダゾピリダジン化合物
US7557103B2 (en) 2005-04-05 2009-07-07 Eli Lilly And Company Imidazopyridazine compounds
US7750000B2 (en) 2005-09-02 2010-07-06 Bayer Schering Pharma Ag Substituted imidazo[1,2b]pyridazines as kinase inhibitors, their preparation and use as medicaments
US20070078136A1 (en) 2005-09-22 2007-04-05 Bristol-Myers Squibb Company Fused heterocyclic compounds useful as kinase modulators
US20100035918A1 (en) 2007-01-30 2010-02-11 Biogen Idec Ma Inc Imidazolone Compounds and Methods of Making and Using the Same

Also Published As

Publication number Publication date
US8143253B2 (en) 2012-03-27
TW200911814A (en) 2009-03-16
EP2183027B1 (fr) 2011-08-31
BRPI0813625A2 (pt) 2014-12-23
CR11207A (es) 2010-02-12
ES2375425T3 (es) 2012-02-29
CO6290714A2 (es) 2011-06-20
EP2183027A1 (fr) 2010-05-12
CL2008002184A1 (es) 2009-05-08
ATE522249T1 (de) 2011-09-15
US20100204235A1 (en) 2010-08-12
ZA201000079B (en) 2010-09-29
JP5090528B2 (ja) 2012-12-05
KR20100034028A (ko) 2010-03-31
TN2010000040A1 (en) 2011-09-26
WO2009013335A1 (fr) 2009-01-29
ECSP109898A (es) 2010-02-26
JP2010534633A (ja) 2010-11-11
AU2008280135B2 (en) 2012-02-23
PE20090506A1 (es) 2009-05-28
SV2010003463A (es) 2010-04-13
KR101150581B1 (ko) 2012-06-11
CA2694261A1 (fr) 2009-01-29
CN101765442A (zh) 2010-06-30
CN101765442B (zh) 2014-09-17
EA201000123A1 (ru) 2010-08-30
AU2008280135A1 (en) 2009-01-29

Similar Documents

Publication Publication Date Title
MA31571B1 (fr) Composes organiques
TN2010000167A1 (en) Organic compounds
TN2010000305A1 (en) Pyrrolopyrimidines and pyrrolopyridines
EA201001687A1 (ru) Производные имидазопиридина в качестве ингибиторов активиноподобной рецепторной киназы ( alk-4 или alk-5 )
MA32536B1 (fr) Composes organiques
TN2009000180A1 (en) NOVEL 1,4-BENZOTHIEPIN-l,1-DIOXIDE DERIVATIVES WHICH ARE SUBSTITUTED WITH BENZYL GROUPS, METHOD FOR PRODUCING DRUGS CONTAINING SAID COMPOUNDS AND USE THEREOF
MX2012013274A (es) Novedosos derivados de la pirimidina.
BR112013033182A2 (pt) compostos imidazopiridinil-aminopiridina substituída
PH12016502394A1 (en) 1, 3, 4-thiadiazole compounds and their use in treating cancer
TW200637863A (en) Organic compounds
WO2013040227A3 (fr) Composés thérapeutiques
BRPI0519292A2 (pt) compostos orgÂnicos
WO2008104473A3 (fr) Inhibiteurs de kinase et procédés d'utilisation de ces derniers
DE602007008691D1 (de) Cyclische sulfone, die zur verwendung als bace-inhibitoren geeignet sind
TW200630366A (en) Organic compounds
GB0428416D0 (en) Organic compounds
TW200800993A (en) Organic compounds
MX2018004696A (es) Analogos de epotilona, metodos de sintesis, metodos de tratamiento y conjugados con farmacos de los mismos.
WO2007068473A3 (fr) Composés organiques
BRPI0507283A (pt) compostos orgánicos
CU20100011A7 (es) Compuestos orgánicos
CU20100147A7 (es) Pirrolo-pirimidinas y pirrolo-piridinas
HK1190714A1 (zh) 作為pim激酶抑制劑的三唑並吡啶化合物